Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Medicare Drug Spending Expected To Surpass Total Current Rx Sales By 2014

Executive Summary

Bush Administration budget estimates suggest that annual Medicare spending on prescription drugs will exceed recent levels of total domestic pharmaceutical sales by 2014
Advertisement

Related Content

Medicare Rx Premium Beats Projections Due To “Robust Competition”
Medicare Rx Premium Beats Projections Due To “Robust Competition”
Medicare Part D Costs
HHS Price Negotiation Under Medicare Rx Would Not Beat PBM Prices – CMS
Reimportation Bill From Dorgan/Snowe Includes User Fees To Fund Oversight
Reimportation Bill From Dorgan/Snowe Includes User Fees To Fund Oversight
Medicare Rx Cost Containment Is Priority For Senate Budget Chairman Gregg
Medicare Rx Cost Estimated At $510 Bil. In White House Budget
Medicare Rx Poised For Passage; $26 Bil. In New Funding For Drugs In 2006
Medicare Rx Poised For Passage; $26 Bil. In New Funding For Drugs In 2006

Topics

Advertisement
UsernamePublicRestriction

Register

PS045375

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel